Novavax Inc revenue
Novavax Inc's revenue was $1.12bn in fiscal 2025, up 64.7% on the year before. Since fiscal 2010 ($343,000) it has grown at a compound 71.5% a year. Over the last twelve months it was $414m.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 15 | 22 | 21 | 31 | 36 | 15 | 31 | 34 | 19 | 476 | 1,146 | 1,982 | 984 | 682 | 1,123 | 414 |
| Growth on the year before | — | +>999% | +50.3% | −5.3% | +46.6% | +18.2% | −57.6% | +103.1% | +10.0% | −45.6% | +>999% | +141.0% | +72.9% | −50.4% | −30.7% | +64.7% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | 476 | 1,146 | 1,079 | 640 | 479 | 1,050 | 325 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 54.5% | 65.1% | 70.3% | 93.5% | 78.6% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $685M | 61.0% | ▲ 221.3% |
| Nuvaxovid Sales (part of Products) | $625M | 91.3% | ▲ 228.7% |
| Supply Sales (part of Products) | $59.9M | 8.7% | ▲ 160.3% |
| Licensing Royalties and Other | $438M | 39.0% | ▼ 6.5% |
| Grant | $0 | 0.0% | — |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| Rest of North America | $576M | 51.2% | ▲ 12801.6% |
| United States | $406M | 36.1% | ▼ 22.4% |
| Rest of The World | $126M | 11.3% | ▲ 114.3% |
| Europe | $15.7M | 1.4% | ▼ 83.6% |
From Novavax Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Novavax Inc | $414m | -61.6% | -36.3% |
| Meiragtx Holdings plc | $398m | 948.3% | 296.0% |
| Mannkind Corp | $394m | 30.5% | 35.5% |
| Sinovac Biotech LTD | $386m | 6.8% | 66.1% |
| Ardelyx, Inc. | $451m | 16.8% | 75.9% |
| Pharming Group N.V. | $376m | 26.6% | — |
Compare with peers
- Meiragtx Holdings plc revenue
- Mannkind Corp revenue
- Sinovac Biotech LTD revenue
- Ardelyx, Inc. revenue
- Pharming Group N.V. revenue
Head to head: MGTX vs NVAXMNKD vs NVAXNVAX vs SVA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies